Best Grants for Cancer Nonprofits in Northern Mariana Islands

The NCI Research Specialist Award (R50) supports clinician scientists involved in NCI-funded clinical trials. This funding opportunity encourages the development of stable research careers by providing salary support and autonomy, allowing clinician scientists to contribute to national clinical trial development and implementation. They play a critical role in sustaining the NCI clinical trials network without serving as principal investigators. This award aims to ensure continuity in cancer research careers.

The NCI Research Specialist Award (R50) supports non-tenure track scientists in cancer research who provide essential contributions within laboratories and core facilities. This award aims to enhance research careers for skilled scientists who do not seek independent investigator funding. Eligible candidates must possess an advanced degree, have at least two years of contribution to NCI-funded research, and dedicate a significant portion of their time to this work. The R50 offers salary support and travel funds to recognize and stabilize these vital roles in cancer research.

Cancer research institutions and translational research centers in the Northern Mariana Islands and other U.S. territories can seek funding to advance prevention, early detection, diagnosis, and treatment of organ-specific or closely related cancers. National Institutes of Health SPORE P50 center grants provide US $25,000,000 for state-of-the-art, human biology-based translational cancer research with clear clinical endpoints.

The Radiation Oncology-Biology Integration Network (ROBIN) Centers, funded by the National Cancer Institute (NCI), aims to enhance national radiation oncology infrastructure through collaborative research. This initiative supports studies on biological responses to radiation treatment in cancer patients, focusing on understanding tumor and tissue changes. By integrating various scientific disciplines and collecting comprehensive data, ROBIN intends to improve cancer care, optimize treatment strategies, and accelerate translational discoveries to enhance patient outcomes.

The Paul Calabresi Career Development Award for Clinical Oncology aims to enhance the training of clinician-scientists in clinical and translational cancer research. This funding opportunity encourages the career growth of researchers but does not permit Scholars to lead independent clinical trials. Instead, it allows participation in clinical trials under the mentorship of an experienced researcher, fostering a collaborative approach to cancer research.

The DoW Rare Cancers Concept Award for FY26 promotes groundbreaking ideas in rare cancer research. This award encourages innovative applications that explore novel courses of investigation without requiring preliminary data. Unique to this program is the prohibition against mentioning the Principal Investigator or collaborators in the proposal materials, ensuring an unbiased review process. This funding opportunity aims to advance scientific discovery in the rare cancer domain.

The DoW Rare Cancers Idea Development Award promotes innovative research ideas for rare cancers, encouraging applicants to provide preliminary data and exploratory aims. This funding opportunity, offered by the US DOD: U.S. Army Medical Command, seeks projects with the potential for high-impact findings that can significantly benefit the patient community. It aims to foster new avenues of investigation and support discovery-driven research in the field of rare cancers.

The 2026 Rare Cancers Research Program Resource and Community Development Award aims to enhance rare cancer research through improved resources and datasets. It addresses critical gaps in research resources, communication strategies, and data sharing infrastructures. Key features include engaging patient advocates throughout the research process and ensuring sustainability of community platforms. This funding opportunity emphasizes community building and the dissemination of findings to benefit scientific and patient communities alike.

The DoW Kidney Cancer Early-Career Scholar Award is a unique initiative by the Academy of Kidney Cancer Investigators, established in FY19. It aims to foster innovative kidney cancer research through a mentoring program that pairs early-career scholars with experienced mentors. This program not only enhances research capabilities but also builds a robust network of kidney cancer researchers. By supporting promising scholars, the initiative aspires to advance the field and improve treatment outcomes for kidney cancer patients.

The FY26 Kidney Cancer Research Program's Idea Development Award supports innovative research that enhances understanding of kidney cancer, aimed at improving patient outcomes. Proposals should feature a strong hypothesis and a detailed research plan, with team members experienced in kidney cancer research. A unique aspect is the Partnering Principal Investigator option, fostering collaboration between two investigators, ensuring comprehensive project development while allowing for distinct submissions. This award emphasizes impactful partnerships to drive advancements in the field.

The National Cancer Institute (NCI) invites applications for innovative technologies aimed at cancer research and clinical care. This funding opportunity supports early-stage projects focused on proof-of-concept studies to assess the feasibility of new methods and tools. Applications should demonstrate significant technical innovation, targeting advancements in cancer biology, early detection, clinical diagnosis, treatment, and epidemiology. Technologies may include novel analysis platforms, imaging technologies, and biospecimen processing innovations, with a focus on cancer applications.

The Radiation Oncology Institute (ROI) Innovation Awards, offered by the American Society for Radiation Oncology, aim to accelerate innovative ideas in radiation therapy. Currently accepting applications for the 2026 awards, the program focuses on optimizing the combination of radiation therapy and immunotherapy to enhance cancer treatment outcomes. By supporting practical research, ROI strives to transform clinical practices and improve patient care in the fight against cancer.

Pfizer is offering a grant opportunity for independent medical education initiatives focused on Muscle Invasive Bladder Cancer (MIBC). This program aims to address the current knowledge gaps among healthcare professionals regarding emerging treatment data and its potential impact on clinical practices. By collaborating with Astellas, Pfizer seeks proposals that enhance awareness and understanding of the evolving MIBC landscape, ultimately improving patient outcomes in this critical area of unmet medical need.

The 2026 Radiation Oncology Institute- Innovation Awards aim to advance cancer treatment by integrating radiation therapy with immunotherapy. Researchers are invited to submit proposals that explore optimal combinations of these modalities to enhance patient outcomes. Funding of up to $100,000 over two years will support projects focused on identifying effective treatment strategies, understanding mechanisms of synergy, and improving access to care. This initiative represents a significant opportunity for innovative research in oncology.

Incyte Corporation invites organizations to submit membership requests aimed at enhancing healthcare access for patients and advocates. As a biopharmaceutical leader, Incyte supports initiatives that align with its mission to improve patient lives through grants and contributions. Eligible entities include medical schools, associations, non-profits, and advocacy groups. Requests should comply with Incyte's regulatory standards and be submitted at least 60 days prior to the required decision date.

Incyte Corporation, a biopharmaceutical leader, offers healthcare sponsorships to support organizations focused on improving patient care and access to healthcare information. Eligible applicants include medical schools, associations, non-profits, advocacy groups, and hospitals. Requests should align with Incyte's commitment to enhancing the lives of patients affected by cancer and other diseases, ensuring compliance with regulatory guidelines. Organizations must enter a written agreement with Incyte to receive funding.

The ACS-ASTRO Felix Feng, MD Clinician Scientist Development Award supports practicing radiation oncologists engaged in research that enhances health across the cancer continuum. Funded by the American Cancer Society and ASTRO, this award provides $730,000 over three to five years, aiming to advance the field of radiation oncology and improve patient care through innovative research and collaboration.

The ASTRO-ACS Clinician Scientist Development Award aims to support full-time faculty members in radiation oncology who aspire to become independent investigators. Co-funded by the American Cancer Society and the American Society for Radiation Oncology, this grant provides $135,000 per year for 3 to 5 years, along with 8% allowable indirect costs. It encourages applications from underrepresented groups and those with disabilities, fostering diversity in cancer research.

The Cancer Care Specialists of Illinois Scholarship offers financial assistance for tuition to high school seniors and healthcare professionals in oncology/hematology within Central and Southern Illinois. The scholarship supports educational pursuits and professional development in these fields. Applications are accepted monthly, with a deadline for 2025 set for December 1st. Eligible candidates must maintain a GPA of 3.0 and reside in specific counties, ensuring support for local talent in healthcare.

This funding opportunity from the Patient-Centered Outcomes Research Institute aims to enhance health decision-making through comparative clinical effectiveness research, focusing on critical areas such as cancer, maternal health, and mental health. The initiative encourages robust observational studies that utilize existing data to derive patient-centered insights. Applications must address specific themes approved by PCORI and demonstrate potential benefits to the U.S. healthcare system, thus ensuring relevance and stakeholder engagement in research efforts.

The Patient-Centered Outcomes Research Institute (PCORI) is announcing funding for comparative clinical effectiveness research across the cancer care continuum. This initiative aims to empower researcher-community partnerships to tackle significant healthcare challenges faced by patients and caregivers in the U.S. The focus is on enhancing care delivery and outcomes by addressing barriers to screening, treatment, and follow-up care for cancer patients. Applications are encouraged to identify strategies that improve patient-centered outcomes.

The Pinetop Assistance League (PAL) Grant provides crucial financial support to elderly blues musicians, ensuring their well-being during emergencies. This grant, part of the Pinetop Perkins Foundation's mission, offers assistance for medical expenses, home care, and essential living costs. Eligible applicants must be professional artists aged 50 or older with a household income below $35,000. By addressing these needs, PAL plays a vital role in preserving the legacy and care of blues musicians.

The Amyloidosis Fund, managed by the HealthWell Foundation, provides essential financial assistance to underinsured patients facing treatment costs for Amyloidosis. The program covers prescription copays, insurance premiums, and related expenses, ensuring that patients can access necessary medications without financial strain. With a maximum award of $8,000, the fund aims to alleviate the burden of healthcare costs for those diagnosed with this complex disease, promoting better health outcomes and quality of life for patients across the United States.

The Cancer-Related Behavioral Health Fund, established by the HealthWell Foundation, provides financial assistance to individuals diagnosed with cancer for behavioral health treatments. This fund covers costs associated with prescription drugs, counseling services, and transportation. Aiming to alleviate financial burdens, it ensures that underinsured patients can access necessary care without delay. In 2024, the foundation awarded over $1.2 billion, emphasizing its commitment to improving health outcomes for cancer patients across the United States.

The Chronic Lymphocytic Leukemia Fund, managed by the HealthWell Foundation, aims to alleviate financial burdens for underinsured patients battling chronic lymphocytic leukemia (CLL). This fund provides essential support for prescription copays and premiums, ensuring that patients can access necessary treatments without the stress of financial constraints. Since its inception, the foundation has awarded over $1.2 billion in grants, helping more than 1.1 million patients. The initiative emphasizes the importance of accessible healthcare and aims to improve the quality of life for those affected by this condition.

The Mantle Cell Lymphoma Fund, managed by the HealthWell Foundation, provides financial assistance to underinsured patients diagnosed with Mantle Cell Lymphoma. The fund covers prescription drug copays and Medicare Part B premiums, with a maximum award of $8,500. Eligible patients must have insurance that covers their medication and meet specific income guidelines. The foundation aims to reduce financial barriers to essential treatments, ensuring that patients receive necessary care without undue financial strain.

The ACS - Fanconi Cancer Foundation Discovery Boost Grant invites innovative proposals for translational cancer research addressing the challenges faced by individuals with Fanconi anemia (FA). This grant supports high-risk, high-reward projects aimed at improving detection, prevention, or treatment of FA-related cancers. With funding of up to $135,000 per year for two years, it encourages research in early detection technologies, prevention mechanisms, and therapeutic strategies tailored to the unique sensitivities of the FA population.